Is Black Diamond Therapeutics Inc (BDTX) Stock About to Get Hot Monday?

Overall market sentiment has been high on Black Diamond Therapeutics Inc (BDTX) stock lately. BDTX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Black Diamond Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BDTX!

See Full BDTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With BDTX Stock Today?

Black Diamond Therapeutics Inc (BDTX) stock has risen 2.58% while the S&P 500 has fallen -0.04% as of 1:05 PM on Monday, Nov 6. BDTX has risen $0.05 from the previous closing price of $1.90 on volume of 272,285 shares. Over the past year the S&P 500 is higher by 14.44% while BDTX has fallen -11.76%. BDTX lost -$2.27 per share in the over the last 12 months. To screen for more stocks like Black Diamond Therapeutics Inc click here.

More About Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. Click Here to get the full Stock Report for Black Diamond Therapeutics Inc stock.